This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Regulus Therapeutics Inc said interim mid-stage data for its hepatitis C combination drug showed it had the potential to sharply reduce the duration of the treatment to four weeks from 12 weeks.
The company’s shares recorded their best day in more than 15 months, rising as much as 41 percent to $8.85 in heavy trading on Wednesday.
Regulus tested its injectable drug, RG-101, separately with FDA-approved hepatitis C drugs such as Gilead Sciences Inc’s Harvoni, Johnson & Johnson’s Olysio, and Bristol Myers Squibb’s Daklinza.
See Regulus Press Release Here: http://ir.regulusrx.com/releasedetail.cfm?ReleaseID=955249
Read more: http://www.reuters.com/article/us-regulus-study-idUSKCN0VQ1HL